In this study of heavily pretreated patients, 83 were eligible for response evaluation. An objective response was observed in 29% of patients, with 6% achieving a complete response (CR/CRu), 23% achieving a partial response and 19% showing stable disease.
According to non-Hodgkin’s lymphoma (NHL) histology, objective response was 36% in mantle cell lymphoma, 22% in diffuse large b-cell lymphoma, 33% in follicular lymphoma (grade three) and 50% in transformed lymphoma. These responses included several patients that had been refractory to their prior therapies, including rituxamab based regimens.
Myron Czuczman, head of lymphoma/myeloma section for department of medicine at Roswell Park Cancer Institute, said: “These data demonstrate that lenalidomide has activity in relapsed/refractory aggressive NHL with a favorable safety profile. Early results from this large international study appear to confirm the results obtained from a previous, smaller, US-based Phase II study.”